Related Experiment Video
Updated: Jan 16, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Balancing Bleeding and Ischemic Risks: A Systematic Review of Dual Versus Triple Therapy After Percutaneous Coronary
Abubakar Gapizov1, Ahmad Mohammad2, Shivam Singla3
1Internal Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, New York, USA.
Insights
Dual antithrombotic therapy, combining a non-vitamin K oral anticoagulant with a P2Y12 inhibitor, reduces bleeding in atrial fibrillation patients undergoing percutaneous coronary intervention compared to triple therapy, without increasing ischemic events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) often require antithrombotic therapy.
- Balancing the risk of ischemic events and bleeding is crucial in this population.
- Current guidelines consider both dual and triple antithrombotic strategies.
Purpose of the Study:
- To systematically review and compare the efficacy and safety of dual versus triple antithrombotic therapy.
- To evaluate outcomes in patients with atrial fibrillation who have undergone percutaneous coronary intervention.
Main Methods:
- Systematic review of four randomized controlled trials (RCTs).
- Inclusion of diverse patient populations and treatment strategies.
- Comparative analysis of dual therapy (non-vitamin K oral anticoagulant + P2Y12 inhibitor) versus triple therapy.
Main Results:
- Dual therapy significantly reduced bleeding complications compared to triple therapy.
- Ischemic event rates (myocardial infarction, stroke, stent thrombosis) were comparable between dual and triple therapy.
- Larger trials supported early aspirin withdrawal, while smaller trials had limitations.
Conclusions:
- Dual antithrombotic therapy is generally preferred for AF patients undergoing PCI due to a better safety profile.
- Triple therapy may be considered for select high-ischemic-risk patients for a limited duration.
- Individualized antithrombotic strategies are essential for optimizing patient outcomes.
Abstract:
This systematic review evaluates the comparative efficacy and safety of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. A comprehensive literature search identified four randomized controlled trials encompassing diverse populations and treatment strategies. Dual therapy, consisting of a non-vitamin K oral anticoagulant combined with a single P2Y12 inhibitor, consistently demonstrated a reduction in bleeding complications compared to conventional triple therapy without compromising protection against ischemic events such as myocardial infarction, stroke, or stent thrombosis. While the larger multicenter trials provided robust evidence supporting the safety of early aspirin withdrawal, smaller trials were limited by sample size and early termination, restricting the generalizability of their findings. Nevertheless, the overall evidence suggests that dual therapy should be considered the preferred approach for most patients, with triple therapy reserved for carefully selected individuals at high ischemic risk where a short course may provide incremental benefit. These findings support the growing shift in clinical practice toward individualized antithrombotic strategies that optimize both safety and efficacy in this complex patient population.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Atherosclerosis III: Management